Finnish-Swiss biopharmaceutical company Aurealis Pharma has raised 4.9 million euros in funding that will go towards advancing its chronic wound and cancer treatment products.
The post Aurealis Pharma raises EUR 4.9 million appeared first on Good News from Finland.